Mood Disorders News

ATLANTA —Mobile self-report smartphone applications may be useful in monitoring depression symptoms, as data presented here indicated depression symptoms reported on a mobile application correlated with physician-administered measurements.

ATLANTA — Vraylar was generally safe, well-tolerated and effective in FDA-approved dose ranges among individuals with schizophrenia or bipolar I disorder, according to data presented at the American Psychiatric Association Annual Meeting.

Recent findings in Harvard Review of Psychiatry suggest screening for postpartum depression should occur soon after delivery and then throughout the postpartum period and requires follow-up mental health evaluation to be effective.

Individuals with bipolar disorder prescribed lithium had lower rates of self-harm and unintentional injury, compared with their peers prescribed valproate, olanzapine and quetiapine.

Younger age, lower education and lower income increased risk for poor mental health among gay and bisexual men, according to recent findings.

The FDA recently announced that olanzapine, an antipsychotic for treatment of schizophrenia and bipolar disorder, can cause eosinophilia with systemic symptoms.

Addictive use of video games and social media was significantly associated with mental health disorder symptoms, according to recent findings.

Women with severe postpartum psychiatric disorders had higher risk for mortality than women with no psychiatric disorders, and suicide risk was particularly high during the first year post-diagnosis.

BALTIMORE — Data presented at the Pediatric Academic Societies Meeting indicated significant associations between bullying and depression and anxiety in children with developmental disorders.

The FDA has added new warnings to aripiprazole drug labels regarding compulsive or uncontrollable urges to gamble, binge eat, shop and have sex associated with use of the antipsychotic.